FDA Special Emergency Program Will Accelerate COVID-19 Therapies, Says Globaldata
As the COVID-19 pandemic spreads rapidly throughout the world, the urgency of finding a treatment has magnified. The Coronavirus Treatment Acceleration Program (CTAP), a special emergency program created by the Food and Drug Administration (FDA), will accelerate COVID-19 therapies by using all available methods to rapidly deliver new treatments to patients, says GlobalData, a leading data and analytics company.
CTAP seeks to triage requests from scientists and developers so that the FDA can get in touch with them quickly and get them connected with the right staff. The FDA’s aim is to respond within one day after the initial round of requests. Development plans will receive ultra-rapid input with prioritization based on the merits of the project and the stage of development. Protocols will